image-media-type
false
true
CDMO Services
Through each interface, we simplify the journey to the patient
Dedicated to sterile injectables, Terumo Contract Development and Manufacturing Organization (CDMO) provides comprehensive support from early development through commercial manufacturing. By standing at the interfaces between formulation and device, between pharmaceutical company and CDMO, and ultimately between treatment and patient, we help customers navigate complexity across the injectable drug delivery journey. Distinct among CDMOs, we combine development and manufacturing expertise, primary container and injection device capabilities and more than 100 years of experience to understand complex relationships across the injectable drug delivery journey and help simplify the path to market.
media-top
true
image-media-type
WHY IT MATTERS Where sterile injectable development meets commercial manufacturing Bringing a sterile injectable therapy to market requires more than manufacturing expertise alone. It requires coordination across formulation development, primary container development, fill-finish, device assembly and commercialization planning and each decision can affect the next interface in the product journey. A connected Deviceuticals™ approach helps pharmaceutical and biotechnology companies consider these interfaces together, supporting continuity from development through commercialization and ultimately patient administration. INTEGRATED CDMO EXPERTISE Parenteral CDMO Specialist Terumo Pharmaceutical Solutions provides specialized CDMO services for sterile parenteral drug products in glass vials and proprietary PLAJEX™ polymer prefillable syringes, supporting customers from clinical development through to commercial manufacturing. Full CDMO Service Offering From formulation development, aseptic filling and finishing, and inspection, to device assembly, labelling, packaging, and primary packaging supply of prefillable syringes. Integrated Container and Fill-Finish Expertise Polymer prefilled syringes (PFS) and glass vials are aseptically filled under isolators in ISO 5 (Class A) environments at Terumo's modern manufacturing facilities in Japan and Germany. By combining Quality & Regulatory Support Terumo Pharmaceutical provides regulatory support to its CDMO customers in addition to the supply of quality plastic syringes and needles for medical applications.
media-top
true
PLATFORM ROLE
A Simplified Journey
Within our Deviceuticals™ framework, the CDMO Services platform brings development, fill-finish, assembly, and packaging capabilities that help advance injectable drug products from development to commercialization.
Together with the injectable drug delivery technologies of Injection Devices and the container technologies and prefillable syringe expertise of Primary Containers, CDMO Services can connect these technologies with the drug product to support the development of complete injectable solutions.
image-media-type
media-left
true
pd-y-64
video-media-type
false
pd-y-64
pd-y-32
PLATFORM CAPABILITIES
Explore our CDMO Services
media-top
true
Explore the platform through six focused capability areas.
variation-1-carousel
true
variation-1-carousel
TBD
Primary Container Manufacturing (PFS)
Learn More
variation-1-carousel
TBD
CDMO Drug Product Development and Formulation
Learn More
variation-1-carousel
TBD
CDMO Aseptic Filling
Learn More
variation-1-carousel
TBD
Drug Delivery Device Assembly CDMO Services
Learn More
variation-1-carousel
TBD
CDMO Labelling & Packaging Services
Learn More
variation-1-carousel
TBD
CDMO Regulatory Support Services
Learn More
pd-y-64
pd-y-64
CONNECTED THROUGH DEVICEUTICALS™
One Platform within a Connected Drug Delivery Journey
CDMO Services is one of our three complementary platforms connected through the Deviceuticals™ framework. Dedicated to sterile injectable drug products, it brings together formulation development, primary containers, aseptic fill-finish, device assembly, and commercial manufacturing expertise to help customers navigate critical interfaces across the drug delivery journey. Working alongside our Injection Device and Primary Container platforms, CDMO Services helps bridge the gap between molecule and patient. By considering formulation, container, device, manufacturing, and patient administration as part of an interconnected system, we support a more integrated and streamlined path from clinical development through commercialization.
Explore Deviceuticals™
image-media-type
media-left
true
pd-y-64
INSIGHTS AND RESOURCES
Insights into Sterile Injectable CDMO Services
Access the latest insights into injectable drug delivery, administration and device technologies through our brochure and technical resources.
media-top
true
variation-1
cards-2
variation-1-card
image
CDMO Services Brochure
Official Platform Brochure
Learn more
variation-1-card
nothing
Terumo Pharmaceutical Solutions on Integrated CDMO Services
Michele Guasti | Global Product Manager | Terumo Pharmaceutical Solutions Division
Published on IPI Talking Point 2026
Read more
pd-y-64
FREQUENTLY ASKED QUESTIONS
CDMO Service Platform FAQs
media-top
true
side-image
What CDMO services does Terumo Pharmaceutical Solutions Division offer for sterile injectable drug products?
Terumo Pharmaceutical Solutions Division provides integrated CDMO services for sterile injectable drug products, supporting customers from clinical development through commercial manufacturing. Services include formulation development, aseptic fill-finish, visual inspection, device assembly, labelling, packaging, primary packaging supply, and regulatory support.
How does the CDMO Services Platform fit within the Deviceuticals™ framework?
The CDMO Services Platform brings together expertise in formulation development, aseptic fill-finish, primary containers, device assembly, packaging, and regulatory support within the Deviceuticals™ framework. By working at the interfaces between formulation and device, pharmaceutical company and CDMO, and ultimately treatment and patient, the platform helps simplify complexity across the sterile injectable drug delivery journey.
Through Deviceuticals™, this expertise is connected with the capabilities of our Injection Device and Primary Container platforms, helping pharmaceutical and biotechnology companies benefit from a more integrated approach to development, manufacturing, and delivery from molecule to patient.
What primary container options are available for injectable therapies?
Terumo offers expertise in both glass vials and proprietary PLAJEX™ polymer prefillable syringes. PLAJEX™ combines the functionality of a polymer syringe with established drug containment performance, supporting a wide range of injectable therapies.
Does Terumo provide regulatory support as part of its CDMO services?
Yes. Terumo provides regulatory support throughout development and manufacturing programs, helping customers navigate regulatory requirements while progressing their injectable products toward commercialization.
Where are Terumo's sterile injectable manufacturing facilities located?
Sterile injectable drug products are manufactured at Terumo facilities in Japan (Kofu and Yamaguchi) and Germany (Leverkusen). These facilities support aseptic filling, visual inspection, and commercial manufacturing activities for global pharmaceutical and biotechnology customers.
How does the Deviceuticals™ approach support injectable drug development?
The Deviceuticals™ framework helps pharmaceutical and biotechnology companies consider formulation, primary container, manufacturing, injection device, and patient administration as interconnected interfaces rather than isolated steps. This connected approach supports a more integrated journey from molecule to patient.
DISCUSS YOUR PROJECT
Connect with our experts to simplify your journey from development to commercialization
Whether you are advancing a sterile injectable product in a vial or prefillable syringe, our experts can help you navigate critical interfaces across formulation development, primary container selection, aseptic fill-finish, device assembly, and commercialization. Discover how our integrated CDMO capabilities and Deviceuticals™ framework can help simplify the path from molecule to patient.
Connect with our Experts
Explore Deviceuticals™
media-top
true
pd-y-64